AAFP Issues Summary of 2018 Final Medicare Fee Schedule

Share this content:
AAFP Issues Summary of 2018 Final Medicare Fee Schedule
AAFP Issues Summary of 2018 Final Medicare Fee Schedule

WEDNESDAY, Nov. 29, 2017 (HealthDay News) -- A four-page executive summary of the 2018 final Medicare physician fee schedule that was released by the Centers for Medicare & Medicaid Services (CMS) has been published by the American Academy of Family Physicians.

The report highlights the key provisions, including a 0.3 percent increase in the 2018 conversion factor, to $35.999; however, physicians will not receive the full positive 0.5 percent update in 2018 called for in the Medicare Access and CHIP Reauthorization Act since CMS was not able to fully meet the misvalued code target required by law.

Changes have been made to the value-based payment modifier and its physician feedback program. The final rule decreases the downward payment adjustment physicians will receive for not meeting Physician Quality Reporting System criteria. The CMS will begin the appropriate use criteria for advanced diagnostic imaging services with an educational and operations testing year in 2020; from mid-2018 through 2019, a voluntary physician participation period will run. The Medicare Diabetes Prevention Program (MDPP) is also addressed in the final rule, with addition of policies necessary to start furnishing MDPP services in 2018.

Other issues covered by the final rule include establishment of payment rates for nonexcepted items and services, changes to the clinical quality measure reporting requirements, and finalization of new policies for the Medicare Shared Savings Program.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »